YOLFTbeta
Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc. Common Stock

MSLE · NASDAQ · Healthcare / Biotechnology

6.63USD-0.21 (-3.00%)

Price History

Full chart

Market Stats

Previous Close6.83
Open6.85
Day Range6.59 – 7.14
52-Week Range5.30 – 13.40
Volume47.72K
Market Cap184.58M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.95
Dividend Yield0.00%
Beta1.14
50-Day Avg9.50
200-Day Avg8.35

About

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Francis Gleeson B.B.A. M.B.A
  • Employees18
  • HeadquartersRoyal Bank Plaza, Toronto, ON, Canada, M5J 2J1, USA
  • Websitehttps://satellos.com

Leadership

  • Mr. Francis Gleeson B.B.A. M.B.ACo-Founder, CEO, President & Director · b. 1955
  • Ms. Elizabeth Williams C.A., CPACFO & Corporate Secretary · b. 1978
  • Dr. Philip Lambert M.A., Ph.D.Chief Scientific Officer · b. 1969
  • Dr. Wildon Farwell M.D., M.P.H.Chief Medical Officer · b. 1976
  • Dr. Michael A. Rudnicki Ph.D.Co-Founder & Chief Discovery Officer · b. 1962
  • Mr. J. Robert Hall CFASenior Vice President of Finance & Administration
  • Dr. Ryan Mitchell Ph.D.Senior VP & Head of Corporate Development
  • Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A.Strategic Advisor · b. 1960
  • Ms. Desiree ChanChief of Staff
  • Ms. Antoinette Paone M.B.A., M.S.Chief Development Officer & Head of Regulatory Affairs · b. 1979

Financials

Income Statement

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---100.55K----------00000
Cost of Revenue--471.59K-109.06K88.01K82.63K47.46K21.95K27.62K23.83K1.53K3.15K892.78K166.94K3.73M5.28K19.99K5.09K
Gross Profit---471.59K--109.06K-88.01K-82.63K-47.46K-21.95K-27.62K-23.83K-1.53K-3.15K-892.78K-166.94K-3.73M-5.28K-19.99K-5.09K
Operating Expense--1.81M-2.36M3.58M5.74M2.11M2.18M1.21M1.47M2.19M2.26M1.88M6.48M4.69M11.65M19.36M26.45M
Operating Income-5.15M-2.37M-2.28M-3.12M-2.47M-3.67M-5.83M-2.16M-2.21M-1.24M-1.49M-2.19M-2.27M-2.77M-6.65M-8.43M-11.66M-19.38M-26.46M
Operating Margin----3106.28%---------------
EBITDA-5.04M-2.27M-2.16M-3.01M-2.36M-3.58M-5.74M-2.11M-2.18M-1.21M-1.47M-2.19M-2.26M-1.61M-4.72M-8.09M-11.84M-19.56M-26.45M
EBITDA Margin----2995.72%---------------
Net Income-5.17M-2.40M-2.31M-3.12M-1.03M-3.65M-5.38M-1.92M-1.79M-1.50M-1.26M-1.70M-1.99M-1.58M-15.51M-11.32M-11.98M-19.58M-24.87M
Net Income Margin----3104.66%---------------
R&D3.70M1.24M1.13M1.67M1.03M2.21M3.79M594.10K625.69K568.80K798.52K1.42M942.49K892.78K2.00M3.73M6.65M13.66M18.43M
R&D as % of Total Revenue---1664.31%---------------
Interest Expense-------------499772.80K0133.42K0-

Balance Sheet

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.27M1.28M4.63M2.69M2.94M3.02M3.73M6.77M3.89M2.47M1.40M177.61K1.51M1.13M9.87M6.14M44.30M50.88M31.89M
Total Liabilities780.80K387.29K323.03K293.31K254.62K965.94K2.50M1.51M114.92K139.24K292.51K800.13K829.64K1.32M1.65M2.80M3.62M3.59M4.11M
Total Equity2.49M894.78K4.31M2.40M2.69M2.05M1.23M5.26M3.77M2.33M1.10M-622.52K678.67K-184.25K8.22M3.34M40.67M47.28M27.78M
Cash1.88M542.52K1.39M635.79K255.03K600.83K1.05M3.53M2.72M2.38M1.14M10.11K1.02M709.08K3.82M1.90M22.07M40.18M9.80M
Total Debt-------------1.10M-----
Net Debt-1.88M-542.52K-1.39M-635.79K-255.03K-600.83K-1.05M-3.53M-2.72M-2.38M-1.14M-10.11K-1.02M386.70K-3.82M-1.90M-22.07M-40.18M-9.80M

Cash Flow

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.90M-2.08M-2.12M-2.68M-1.93M-2.77M-3.57M-2.71M-3.09M-1.34M-1.10M-2.30M-1.66M-3.95M-5.66M-14.42M-17.40M-23.60M
Investing Cash Flow585.28K21.08K-2.52M1.10M513.65K408.07K-131.09K-849.68K1.99M-4.06K-3.19K-6.15K-1.36M-2.21K-17.54M4.42M-9.42M
Financing Cash Flow4.24M953.64K5.41M825.58K1.04M2.70M4.20M5.99M---3.31M1.98M5.84M2.75M50.95M37.27M2.24M
Capital Expenditure10.91K15.80K3.07K6.88K2.10K2.98K3.0301.85K4.07K3.18K6.16K05.68K2.21K18.00K4.18K6.00K
Free Cash Flow-3.91M-2.10M-2.13M-2.69M-1.93M-2.77M-3.57M-2.71M-3.09M-1.35M-1.10M-2.30M-1.66M-3.95M-4.26M-14.44M-17.41M-23.60M
Dividends Paid--------------00--
FCF to OCF100.28%100.76%100.14%100.26%100.11%100.11%100.00%100.00%100.06%100.30%100.29%100.27%100.00%100.14%75.28%100.12%100.02%100.03%
Dividend Paid to FCF--------------0.00%0.00%--

Earnings

Report DateJun 30, 2012Nov 29, 2012Dec 31, 2012May 30, 2013Aug 27, 2013Nov 28, 2013Dec 31, 2013May 30, 2014Aug 29, 2014Dec 1, 2014Dec 31, 2014May 29, 2015Aug 27, 2015Nov 25, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Nov 29, 2021Dec 31, 2021May 31, 2022Aug 30, 2022Nov 23, 2022Dec 31, 2022May 30, 2023Aug 27, 2023Nov 22, 2023Mar 27, 2024May 14, 2024Aug 12, 2024Nov 13, 2024Mar 26, 2025May 13, 2025Aug 13, 2025Nov 14, 2025Mar 27, 2026May 15, 2026Aug 13, 2026Nov 13, 2026
EPS Estimate------------------------------------------0.60--0.48-0.36-0.24-0.12--0.61-0.62-----0.06-0.59-0.38-0.44
EPS Actual-3.36-4.62-6.40-8.44-3.31-6.83-4.58-1.93-3.81-0.810.39-0.58-1.71-0.36-1.21-1.78-0.43-0.46-0.49-0.82-0.70-0.70-0.48-0.94-1.37-0.91-0.53-0.68-0.63-0.72-0.80-0.76-0.36-0.23-0.38-0.91-0.55-4.08-0.73-0.61-0.64-0.45-1.07-0.35-0.44-0.26-0.53-0.55-0.44-0.69-0.32-0.44-0.39-0.42-0.50-0.53-0.56-
Surprise-----------------------------------------25.00%-27.08%-22.22%-8.33%-341.67%-27.87%-11.29%-----733.33%10.17%-47.37%-
Timing-----------------------------------------After-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursPre-market-----Pre-marketAfter-hours-

Key Statistics & Ratios

Market Cap184.58M
Enterprise Value121.71M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.04
EPS-1.95
Book Value2.88
Revenue (TTM)0
Gross Profit (TTM)-9.48M
EBITDA-35.82M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-70.45%
Return on Assets-41.89%
Shares Outstanding21.22M
Shares Float18.02M
Beta1.14
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
49.70%
Insiders
6.37%
Retail / Other
43.93%

Top Institutional Holders

  • Franklin Templeton Inc
    938.67K4.42%
  • Siren, L.L.C.
    892.07K4.20%
  • Vivo Capital, LLC
    813.67K3.84%
  • Point72 Asset Management, L.P.
    690.78K3.26%
  • Woodline Partners LP
    500.43K2.36%
  • Sphera Funds Management Ltd.
    489.21K2.31%
  • Suvretta Capital Management, LLC
    475.00K2.24%
  • Avidity Partners Management LP
    387.77K1.83%
  • Saturn V Capital Management LLC
    350.00K1.65%
  • Soleus Capital Management, L.P.
    314.36K1.48%
  • 683 Capital Management LLC
    230.83K1.09%
  • ADAR1 Capital Management LLC
    222.56K1.05%
  • Millennium Management LLC
    152.77K0.72%
  • Adage Capital Partners Gp LLC
    150.00K0.71%
  • Empery Asset Management, LP
    107.10K0.50%
  • Stonepine Capital Management Llc
    100.00K0.47%
  • Citadel Advisors Llc
    67.74K0.32%
  • HRT FINANCIAL LLC
    30.46K0.14%

Top Fund Holders

  • Franklin Biotechnology Discv A(acc)USD
    595.43K2.81%
  • Franklin Biotechnology Discovery A
    343.24K1.62%